Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization (NCT06229080) | Clinical Trial Compass
CompletedNot Applicable
Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization
South Korea20 participantsStarted 2023-03-15
Plain-language summary
The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90 radioembolization of liver cancer.
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Adults aged 19 years or older
. Patients diagnosed with primary or metastatic liver cancer based on histological and/or radiological findings
. Patients determined, following medical, surgical, or multidisciplinary evaluation, to be best treated by radioembolization
. Patients with no history of local treatments (e.g., ablation, chemoembolization) to the same hepatic lobe within the past year
. Child-Pugh class A
. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower
. Patients whose treatment area, as determined by planning angiography, includes at least two liver segments
. Patients for whom normal liver tissue constitutes 50% or more of the treatment volume
Exclusion criteria
. Liver cancer with vascular invasion
. For primary liver cancer, patients who have been diagnosed with a malignancy other than the primary liver cancer within 2 years prior to study enrollment
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver